MabVax Therapeutics announces completion of enrollment and dosing in phase 1 trial
MabVax Therapeutics announced completion of enrollment and dosing of all patients in the initial cohort of the Phase 1 clinical trial evaluating the Company's new human antibody-based radioimmunotherapy product MVT-1075 for the treatment of pancreatic, colon and lung cancer. December 13, 2017